Thomas G. Wiggans
Chairperson of the BoardMr. Thomas G. Wiggans, also known as Tom, was Independent Director of Pacira BioSciences, Inc. from June 9, 2026 until November 17, 2026. Mr. Wiggans served as Independent Chairman of Jasper Therapeutics, Inc. since November 1, 2023 until January 5, 2026 and serves as Executive Chairman from January 5, 2026. He served as Independent Director at CymaBay Therapeutics, Inc. since April 2021 until March 22, 2024. He serves as an Executive Chairman of Follica, Inc. since January 2021. He served as Chief Executive Officer and Chair of the Board of Directors at Pardes Biosciences, Inc. since March 1, 2022. Mr. Wiggans had been Chairman and Independent Director of Annexon Inc. since February 05, 2021 until June 11, 2026 and since February 2017 until June 11, 2026 respectively. He had been an Independent Director at Forma Therapeutics Holdings, Inc. since September 2020 until October 14, 2022 and Board Member of Forma Therapeutics, Inc. Mr. Wiggans Co-founded Dermira, Inc. in August 2010 and had been its Chief Executive Officer since September 2010 until February 2020. He serves as an Advisor at Stiefel Laboratories. He has extensive experience from the pharmaceutical and biotechnology industries. He served as the Chief Executive Officer of Peplin Inc. since August 15, 2008 until November 2009. He served as the Chief Executive Officer of Connetics Corporation from July 1994 to December 2006 and served as its President from July 1994 to February 16, 2005. From February 1992 to April 1994, he served as the President and Chief Operating Officer at Cyto Therapeutics Inc. From 1980 to February 1992, he served in various positions at Ares-Serono Group, including President of its U.S. Pharmaceutical Operations and Managing Director of Ares-Serono Group’s U.K. Pharmaceutical Operations. Mr. Wiggans began his career with Eli Lilly and Company. From 1976 to 1980, Mr. Wiggans served various sales and marketing positions with Eli Lilly & Co. Prior to Connetics, he spent many years with the Ares-Serono Group in various management positions including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. He served as the Chairman of Excaliard Pharmaceuticals, Inc. since October 2010 until December 2011. He served as Chairman of Dermira, Inc. since April 2014 until February 19, 2020 and served as its Director since August 2010 until February 19, 2020. He served as the Chairman of Biotechnology Institute, The. He served as the Chairman of Connetics Corporation from January 1, 2006 to December 2006. He served as the Chairman and Director of Peplin Inc. (alternate name, Peplin Limited) since July 2007 until November 2009. Mr. Wiggans serves as a Director of CellExSys, Inc. He is a Director at Annexon Biosciences, Inc. He serves on the Board of Overseers of the Hoover Institution at Stanford University. He is a long-standing member of the board of directors of BIO, as well as a member of the board of trustees of the University of Kansas Endowment Association. He served as Director of Neothetics, Inc. (alternate name, Lithera, Inc.) from April 2011 to September 10, 2014 and Onyx Pharmaceuticals, Inc. from March 10, 2005 to October 2013. He served as a Director of Sangamo Therapeutics, Inc. (alternate name, Sangamo Biosciences Inc.) from June 2008 to June 21, 2012 and Pernix Sleep, Inc. (alternate name, Somaxon Pharmaceuticals Inc.) from June 2008 to May 2012. He served as a Director of Victory Pharma, Inc. and Corthera Inc. Mr. Wiggans served as a Director of Biotechnology Innovation Organization (alternate name, Biotechnology Industry Organization). He served as a Director of Abgenix Inc. since April 2003. Mr. Wiggans is a veteran biopharmaceutical executive. He served as a Director of Progen Pharmaceuticals, Inc. He served as a Director of Ipsen Biopharmaceuticals, Inc. (alternate name, Tercica Inc.) from April 19, 2005 to October 13, 2006. He served as a Director of Connetics Corporation from July 1994 to December 2006. Mr. Wiggans received a BS Degree in Pharmacy from the University of Kansas and an MBA Degree from Southern Methodist University.
Positions
- Company NameJasper Therapeutics, Inc.Stock CodeJSPRPositionChairperson of the BoardColleagues
- JSJeetinder Singh MahalPresident, CEO, Interim CFO & Director
- MEMatthew E. RosCOO & Interim Corporate Secretary
- MFMatthew FordSenior Vice President of Human Resources
- LPLisa PittSenior Vice President of Regulatory Affairs
- WSWenru SongExecutive VP and Head of R&D
- KVKurt von EmsterDirector
- SLSvetlana LucasDirector
- PJPatrick James CrutcherDirector
